Novartis has acquired Vedere Bio and added a platform for adeno-associated virus-based gene therapy delivery, according to a press release.
The acquisition includes two preclinical optogenetic AAV gene therapy programs for treating inherited retinal dystrophies and geographic atrophy, and technologies such as light-sensing proteins that can be be delivered to retinal cells as well as AAV delivery vectors that enable intravitreal injection treatment, the release said.
“We believe that gene therapy technologies have transformative potential for treating blinding diseases,” Cynthia
Uncategorized